Biotech’s Double-Edged Sword: Extraordinary Funding Run Contributes To Talent Crisis
Company Creation Outpaces Availability Of Experienced Candidates
Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem.
You may also be interested in...
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.
The cancer drug developer was planning to go public later this year, but its series B investor Boxer Capital proposed a merger with its special purpose acquisition corporation, BCTG Acquisition.
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.